Several different mechanisms have been reported to explain the reduced expression of PR in breast and endometrial cancer, including ligand-dependent downregulation [10,11,12,13], miRNA-mediated post-transcriptional suppression [14,15,16,17], hyperactive Akt signaling [18,19,20], and epigenetic factors [21,22,23,24]. Here, AKT1 is linked to endometrial cancer.